Skip to main content
SUDEEPPHRM · Health Care · 2026-08-07

Sudeep Pharma Ltd

MARKET: BULL TOPPING · 2026-08-07
₹957.6
-1.70% today
₹10,815 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends to meet the needs across functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations. In addition, the company is involved in manufacturing, developing, buying, selling, importing, exporting, trading, agency, testing, distributing, consigning, stocking, registering, packing, marketing, refining, and processing of pharmaceuticals, nutraceutical and nutrition products, food ingredients, mineral and vitamin blends, or premixes for infant, human and animal nutrition, and other chemical and healthcare products. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.

Visit company website →
P/E (TTM)
45.2
Forward 34.7
Earnings Growth (YoY)
+7.6%
Revenue +15.7%
ROE
+25.1%
Profit margin +25.8%
vs 52W High
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 35
1w13w26w
Week 35 — mature, watch for distribution
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.77x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
MA20 trending up · +4.0% vs MA50 +10.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Industry has 53 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2025-11-28 → 2026-08-07
S? 36w
2025-11-282026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 36w current
Total tracked: 36 weeks across 1 stage run.
1M
+19.4%
3M
+45.5%
6M
+60.8%
YTD
+54.1%
1Y
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-08-07S
Wk 35 · Vol x
2026-08-06S
Wk 35 · Vol x
2026-08-05S
Wk 35 · Vol x
2026-08-04S
Wk 35 · Vol x
2026-08-03S
Wk 34 · Vol x
2026-07-31S
Wk 34 · Vol x
2026-07-30S
Wk 34 · Vol x
2026-07-29S
Wk 34 · Vol x
2026-07-28S
Wk 34 · Vol x
2026-07-27S
Wk 33 · Vol x
2026-07-24S
Wk 33 · Vol x
2026-07-23S
Wk 33 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹831.4
200 DMA
52W High
52W Low
5D Low
₹867.6
Resistance levels (recent highs)
20d High
₹974.2
60d High
₹974.2
120d High
₹974.2
250d High
Next resistance
+1.7%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.